SILVER SPRING, Md. - Development of leukemia in two French gene therapy patients coupled with limited data prompted an FDA panel of advisers to conclude that gene therapy trials in X-linked severe combined immunodeficiency (SCID) should not go forward unless there are no other treatment options available. (BioWorld Today) Read More